3D biomimetic microgel platform for multiple myeloma: Approaching tumor microenvironment on cell lines and patient-derived cells
Source abstract
Abstract
This work aimed to develop and characterize a three-dimensional culture platform that recreates the tumor microenvironment of multiple myeloma cells (MMCs), focusing on how atypical plasma cells (aPCs) interact with other bone marrow cells and extracellular matrix (ECM) components to develop drug resistance. The biomimetic platform consists of a static system based on a conical agarose geometry that facilitates the agglomeration and proliferation of aPCs. Magnetic alginate microgels, manufactured by microfluidics, configure the ECM through a layer-by-layer functionalization with collagen, hyaluronic acid, chondroitin sulfate, and heparin. In addition, bone marrow mesenchymal stem cell (BMMSC) pellets were integrated to simulate direct and indirect interactions between BMMSCs and MMCs. The platform has been validated with three lines of MMCs (RPMI8226, MM1S, U266) and the patients' mononuclear cell fraction collected from bone marrow aspirates extracted in two Spanish Hospitals. The microgel analysis aimed to verify stability and to characterize the presence of the different coatings. Biological studies have investigated the proliferation and resistance to drug treatments in MM cell lines. In addition, patient-derived cells were cultured for up to 14 days to study the survival and possible immunophenotypic changes of the atypical plasma cell (aPC) fraction.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Multiple Myeloma Research and Treatments · 3D Printing in Biomedical Research · Proteoglycans and glycosaminoglycans research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2. Novel local “Off-the-Shelf” immunotherapy for the treatment of myeloma bone disease10.3390/cells12030448 ↗
3. The route of the malignant plasma cell in its survival niche: exploring “Multiple Myelomas,”10.3390/cancers14133271 ↗
4. NCCN Guidelines insights: multiple Myeloma, version 3.201610.6004/jnccn.2016.0046 ↗
5. Current treatment landscape for relapsed and/or refractory multiple myeloma10.1038/nrclinonc.2014.200 ↗
6. How I treat myeloma with new agents10.1182/blood-2017-05-743203 ↗
7. New regimens and directions in the management of newly diagnosed multiple myeloma, am
8. In vitro modeling of non-solid tumors: how far can tissue engineering go?10.3390/ijms21165747 ↗
9. Multiple myeloma10.1016/S0140-6736(21)00135-5 ↗
10. Patient-derived multiple myeloma 3D models for personalized medicine—are we there yet?10.3390/ijms232112888 ↗
11. Cell culture techniques10.1016/B978-0-12-374849-2.00013-6 ↗
12. 2D and 3D cell cultures – a comparison of different types of cancer cell cultures
13. Tumour heterogeneity in the clinic10.1038/nature12627 ↗
14. Tumour heterogeneity and resistance to cancer therapies10.1038/nrclinonc.2017.166 ↗
15. Drug screening in 3D in vitro tumor models: overcoming current pitfalls of efficacy read-outs10.1002/biot.201600505 ↗
16. A comprehensive review of the genomics of multiple myeloma: evolutionary trajectories, gene expression profiling, and emerging therapeutics10.3390/cells10081961 ↗
17. Genomic variability in Multiple Myeloma (MM) patients by race: an analysis of the publicly available mmrf commpass study database10.1182/blood.V128.22.4432.4432 ↗
18. Modulating the stem cell niche for tissue regeneration10.1038/nbt.2978 ↗
19. Pregrado de Hematología
20. The extracellular bone marrow microenvironment—A proteomic comparison of constitutive protein release by in vitro cultured osteoblasts and mesenchymal stem cells
21. Randomized phase II trials: a long-term investment with promising returns10.1093/jnci/djr218 ↗
22. Bioengineering 3D environments for cancer models10.1016/j.addr.2014.06.004 ↗
23. Organoid-based novel technology for antitumor drug screening10.1002/VIW.20250107 ↗
24. Micro pattern-based 3D cell culture platform: an overview of technologies and applications10.1002/EXP.20240469 ↗
25. Possibilities and limitations of an in vitro three-dimensional bone marrow model for the prediction of clinical responses in patients with relapsed multiple myeloma10.3324/haematol.2018.213355 ↗
26. A pilot study of 3D tissue-engineered bone marrow culture as a tool to predict patient response to therapy in multiple myeloma10.1038/s41598-021-98760-9 ↗
27. Ex vivo propagation in a novel 3D high-throughput co-culture system for multiple myeloma10.1007/s00432-021-03854-6 ↗
28. Liposomal drug delivery in an in vitro 3D bone marrow model for multiple myeloma10.2147/IJN.S184262 ↗
29. 3D-Dynamic culture models of multiple myeloma10.1007/978-1-4939-7021-6_13 ↗
30. In vitro models of the crosstalk between multiple myeloma and stromal cells recapitulate the mild NF-κB activation observed in vivo10.1038/s41419-024-07038-1 ↗
31. Protein-functionalized microgel for multiple myeloma cells' 3D culture10.3390/biomedicines10112797 ↗
32. Co-culture of multiple myeloma cell lines and bone marrow mesenchymal stem cells in a 3D microgel environment10.1016/j.bioadv.2025.214243 ↗
33. Biomimetic 3d environment based on microgels as a model for the generation of drug resistance in multiple myeloma10.3390/ma14237121 ↗
34. Novel microgel culture system as semi-solid three-dimensional in vitro model for the study of multiple myeloma proliferation and drug resistance10.1016/j.bioadv.2022.212749 ↗
35. Stability of biomimetically functionalised alginate microspheres as 3D support in cell cultures10.3390/polym14204282 ↗
36. Preparation of monodisperse calcium alginate microcapsules via internal gelation in microfluidic-generated double emulsions10.1016/j.jcis.2013.04.044 ↗
37. Investigation of swelling/degradation behaviour of alginate beads crosslinked with Ca2+ and Ba2+ ions10.1016/j.reactfunctpolym.2004.01.002 ↗
38. The size stability of alginate beads by different ionic crosslinkers10.1155/2017/9304592 ↗
39. Characterisation of bare and tannase-loaded calcium alginate beads by microscopic, thermogravimetric, FTIR and XRD analyses10.1016/j.ijbiomac.2018.04.138 ↗
40. Fourier transform infrared (FTIR) spectroscopy of biological tissues10.1080/05704920701829043 ↗
41. Physicochemical model of alginate–poly-l-lysine microcapsules defined at the micrometric/nanometric scale using ATR-FTIR, XPS, and ToF-SIMS10.1016/j.biomaterials.2005.05.007 ↗
42. Preparation and characterization of photo-cross-linkable methacrylated silk fibroin and methacrylated hyaluronic acid composite hydrogels10.1021/acs.biomac.4c00319 ↗
43. Crosslinkers for polysaccharides and proteins: synthesis conditions, mechanisms, and crosslinking efficiency, a review10.1016/j.ijbiomac.2022.01.029 ↗
44. Sulfated alginates as heparin analogues: a review of chemical and functional properties10.3390/molecules22050778 ↗
45. Hydrogel based on an alginate-Ca2+/chondroitin sulfate matrix as a potential colon-specific drug delivery system10.1039/c2ra20785k ↗
46. Thermal degradation properties of biobased iron alginate film10.1016/j.jaap.2016.03.014 ↗
47. Effect of calcium ion (cross-linker) concentration on porosity, surface morphology and thermal colouior of calcium alginates prepared from algae (Undaria pinnatifida)10.1016/j.carbpol.2010.03.025 ↗
48. A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma10.1038/s43018-025-01072-4 ↗
49. From biology to clinical practice: the bone marrow microenvironment in multiple myeloma10.3390/jcm14020327 ↗
50. The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor10.1182/blood-2008-07-170464 ↗
51. Major role of the soluble interleukin-6/interleukin-6 receptor complex for the proliferation of interleukin-6-dependent human myeloma cell lines10.1002/eji.1830271232 ↗
52. Interleukin‐6 dependence of advanced malignant plasma cell dyscrasias10.1002/1097-0142(19920315)69:6<1373::AID-CNCR2820690612>3.0.CO;2-1 ↗
53. A review of the cytokine network in multiple myeloma10.1002/cncr.11072 ↗
54. The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential10.18632/oncotarget.8982 ↗
55. Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma10.18632/oncotarget.1736 ↗
56. Targeting hypoxia in solid and haematological malignancies10.1186/s13046-022-02522-y ↗
57. Therapeutic targeting of hypoxia and hypoxia-inducible factor 1 alpha in multiple myeloma10.1016/j.trsl.2014.12.001 ↗
58. Hyaluronic acid induces survival and proliferation of human myeloma cells through an Interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein10.1074/jbc.M003965200 ↗
59. The heparanase/syndecan-1 axis in cancer: mechanisms and therapies10.1111/febs.12168 ↗
60. The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy10.1182/blood-2007-04-082495 ↗
61. Chondroitin sulfate proteoglycan serglycin influences protein cargo loading and functions of tumor-derived exosomes10.18632/oncotarget.20564 ↗
62. Extracellular matrix and its therapeutic potential for cancer treatment10.1038/s41392-021-00544-0 ↗
63. Adhesion molecules—The lifelines of multiple myeloma cells10.1016/j.semcancer.2010.04.003 ↗
64. Cell-surface serglycin promotes adhesion of myeloma cells to collagen type i and affects the expression of matrix metalloproteinases10.1111/febs.12179 ↗
65. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins10.1182/blood-2017-07-797050 ↗
66. Changes in the secretome of tri-dimensional spheroid-cultured human mesenchymal stem cells in vitro by interleukin-1 priming10.1186/s13287-017-0753-5 ↗
67. Poly(ethylene glycol)-based hydrogel microcarriers alter secretory activity of genetically modified mesenchymal stromal cells10.1021/acsbiomaterials.3c00954 ↗
68. MSCs' conditioned media cytokine and growth factor profiles and their impact on macrophage polarization10.1186/s13287-023-03381-w ↗
69. Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis10.1038/s41375-020-0785-1 ↗
70. Network-based analysis of bortezomib pharmacodynamic heterogeneity in multiple myeloma cells10.1124/jpet.118.247924 ↗
71. Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies10.1172/jci.insight.94543 ↗
72. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications10.18632/oncotarget.12643 ↗
73. Drug resistance in multiple myeloma: soldiers and weapons in the bone marrow niche10.3389/fonc.2022.973836 ↗
74. Constitutive activation of STAT3 in myeloma cells cultured in a three-dimensional, reconstructed bone marrow model10.3390/cancers10060206 ↗
75. The molecular interaction of collagen with cell receptors for biological function10.3390/polym14050876 ↗
76. Interactions between Hyaluronan and its receptors (CD44, RHAMM) regulate the activities of inflammation and cancer10.3389/fimmu.2015.00201 ↗
77. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells, Semin10.1016/j.semcancer.2008.03.009 ↗
78. The role of tumor microenvironment in chemoresistance: 3D extracellular matrices as accomplices10.3390/ijms19102861 ↗
79. Bone marrow mesenchymal stromal cells in multiple myeloma: their role as active contributors to myeloma progression10.3390/cancers13112542 ↗
80. Microenvironment drug resistance in multiple myeloma: emerging new players10.18632/oncotarget.10849 ↗
81. Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment10.3389/fonc.2023.1155621 ↗
82. Effects of mesenchymal stem cells from different sources on the biological functions of multiple myeloma cells
83. Davis
84. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis10.4049/jimmunol.171.1.88 ↗
85. Targeting the ubiquitin-proteasome system for cancer therapy10.1517/14728222.2013.815728 ↗
86. Glucocorticoids in multiple myeloma: past, present, and future10.1007/s00277-018-3465-8 ↗
87. Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies
88. NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells10.3892/mmr.2013.1394 ↗
89. Metabolic signature identifies novel targets for drug resistance in multiple myeloma10.1158/0008-5472.CAN-14-3400 ↗
90. BRD4 inhibitor nitroxoline enhances the sensitivity of multiple myeloma cells to bortezomib in vitro and in vivo by promoting mitochondrial pathway-mediated cell apoptosis10.1177/2040620720932686 ↗
91. Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms10.18632/oncotarget.1497 ↗
92. Emerging therapeutic strategies to overcome drug resistance in multiple myeloma10.3390/cancers13071686 ↗
93. Cx43 expressed on bone marrow stromal cells plays an essential role in multiple myeloma cell survival and drug resistance10.5114/aoms.2017.64722 ↗
94. 3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma10.1016/j.biomaterials.2015.09.017 ↗
95. Immunophenotyping in multiple myeloma and related plasma cell disorders10.1016/j.beha.2010.09.002 ↗
96. Understanding the bioactivity and prognostic implication of commonly used surface antigens in multiple myeloma10.3390/jcm11071809 ↗
97. CD56 expression modulates NAD+ metabolic landscape and predicts sensitivity to anti-CD38 therapies in multiple myeloma10.1038/s41408-025-01284-y ↗
98. Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis
99. CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease10.1046/j.1365-2141.2003.04260.x ↗
100. Prognostic value of the expression of CD27 and CD117 in newly diagnosed multiple myeloma patients10.1186/s12865-025-00719-2 ↗